Daratumumab-based triplet regimen extends PFS in advanced multiple myeloma

ORLANDO — A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.The

Read the full article here

Related Articles